18 September 2017 - UK-based drugmaker AstraZeneca (NYSE: AZN) has entered into an agreement with Mauritius-based Aspen Group's Aspen Global Inc business under which AGI will now acquire the residual rights to the established anaesthetic medicines comprising of Diprivan, EMLA,Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin,
Carbocaine and Citanest, the company said.
Local anesthetics are given by injection or topically, and include benzocaine, bupivacaine (Marcaine, Sensorcaine), chloroprocaine (Nesacaine), camphor, dibucaine (Nuper-cainal), levobupivacaine (Chirocaine), lidocaine (Xylocaine, Octocaine), mepivacaine (
Carbocaine, Polocaine), pramoxine, prilocaine (Citanest), procaine (Novocaine), ropivacaine (Naropin), and tetracaine (Pontocaine).